Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug 4;7(3):64.
doi: 10.1208/pt070364.

Evaluation of alternative strategies to optimize ketorolac transdermal delivery

Affiliations

Evaluation of alternative strategies to optimize ketorolac transdermal delivery

Carmelo Puglia et al. AAPS PharmSciTech. .

Abstract

In the present study, 2 alternative strategies to optimize ketorolac transdermal delivery, namely, prodrugs (polyoxyethylene glycol ester derivatives, I-IV) and nanostructured lipid carriers (NLC) were investigated. The synthesized prodrugs were chemically stable and easily degraded to the parent drug in human plasma. Ketorolac-loaded NLC with high drug content could be successfully prepared. The obtained products formulated into gels showed a different trend of drug permeation through human stratum corneum and epidermis. Particularly, skin permeation of ester prodrugs was significantly enhanced, apart from ester IV, compared with ketorolac, while the results of drug release from NLC outlined that these carriers were ineffective in increasing ketorolac percutaneous absorption owing to a high degree of mutual interaction between the drug and carrier lipid matrix. Polyoxyethylene glycol esterification confirmed to be a suitable approach to enhance ketorolac transdermal delivery, while NLC seemed more appropriate for sustained release owing to the possible formation of a drug reservoir into the skin.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Kokki H. Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children. Paediatr Drugs. 2003;5:103–123. - PubMed
    1. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39:86–109. doi: 10.2165/00003495-199039010-00008. - DOI - PubMed
    1. Reinhart DI. Minimizing the adverse effects of ketorolac. Drug Saf. 2000;22:487–497. doi: 10.2165/00002018-200022060-00007. - DOI - PubMed
    1. Parikh DK, Ghosh TK. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech. 2005;6:E144–E149. doi: 10.1208/pt060222. - DOI - PMC - PubMed
    1. Doh HJ, Cho WJ, Yong CS, et al. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J Pharm Sci. 2003;92:1008–1017. doi: 10.1002/jps.10353. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources